Navigation Links
AbbVie Reports Second-Quarter 2014 Financial Results
Date:7/25/2014

lders of record at the close of business on July 15, 2014. 

Full-Year 2014 Outlook
Excluding the potential impact of the transaction with Shire, AbbVie is confirming its recently-increased diluted earnings-per-share guidance for the full-year 2014 of $3.06 to $3.16 on an adjusted basis, or $2.69 to $2.79 on a GAAP basis.  AbbVie's 2014 outlook excludes any potential revenue from the expected 2014 U.S. launch of its hepatitis C (HCV) therapy.  The company's 2014 adjusted diluted earnings-per-share guidance excludes $0.37 per share of intangible asset amortization expense and other specified items primarily associated with certain separation-related costs and ongoing restructuring activities. 

Third-Quarter 2014 Outlook
Excluding the potential impact of the transaction with Shire, AbbVie is issuing diluted earnings-per-share guidance for the third-quarter 2014 of $0.77 to $0.79 on an adjusted basis, or $0.68 to $0.70 on a GAAP basis.  The company's third-quarter adjusted diluted earnings-per-share excludes $0.09 per share of intangible asset amortization expense and other specified items primarily associated with certain separation-related costs and ongoing restructuring activities.

UK City Code
The Full-Year 2014 Outlook and Third-Quarter 2014 Outlook constitute profit forecasts under Rule 28 of the City Code on Takeovers and Mergers issued by the Panel on Takeovers and Mergers (the "Code").

In accordance with Rule 28.4(a) of the Code, the principal assumptions upon which the forecasts are based are included at Schedule 1 to this announcement. In accordance with Rule 28.4(b) of the Code, there is a clear distinction in Schedule 1 between assumptions which the Directors of AbbVie (or other members of AbbVie's management) can influence and those which they cannot influence.

The Third-Quarter 2014 Outlook has been reported on by PricewaterhouseCoopers LLP ("PwC"), the Company's reporti
'/>"/>

SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. AbbVie to Host Second-Quarter Earnings Conference Call
2. AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call
3. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
4. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
5. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
6. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
7. AbbVie Reports Third-Quarter 2013 Financial Results
8. AbbVie Named a Science Top Employer
9. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
10. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
11. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... Biosimilars are not generics and the ... and Drug Administration (FDA) for recognizing that each ... guidance issued today. The FDA,s draft guidance on ... calling for biological products to bear a nonproprietary ... reflects the agency,s thinking that "there is a ...
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... Bermuda, Dec. 16 Celtic Pharmaceutical Holdings L.P. ("Celtic ... preliminary analyses completed on the two double-blinded studies of XERECEPT ... edema, as well as an initial database lock on the ... , The results of these studies ...
... Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time ... MannKind Corporation (Nasdaq: MNKD ) will host ... 3 studies of AFRESA(TM), the company,s ultra rapid acting, inhaled insulin product, ... , , To participate in the live ...
Cached Medicine Technology:Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009 2MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes 2
(Date:8/29/2015)... New York, NY (PRWEB) , ... August 29, ... ... consistently successful results and include treating the localized area with stretching, soft tissue ... and a neutral pelvic position have shown through research to improve treatment ...
(Date:8/28/2015)... ... 2015 , ... Rio Salado College joined nine educational institutions in ... of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by ... Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... No Malaria Day at the Zoo to celebrate children helping children, a thank ... their congregations throughout West Ohio have contributed to the United Methodist initiative to ...
(Date:8/28/2015)... ... , ... With the goal of furthering music education programs in schools, the ... County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best ... the underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a ... for two years, the longest of any cellulite reduction system currently on the market. ... effective solution for their cellulite, according to Dr. Robert Weiss, director of the premier ...
Breaking Medicine News(10 mins):Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... , THURSDAY, Oct. 13 (HealthDay News) -- Human children are ... a new study finds. Researchers compared the responses of ... Republic of Congo sanctuary. Both the children and the ... own or with a partner. Individuals could pull two ends ...
... on the Nature review website, provides evidence of ... use of these stem cells to treat humans, through perspective ... to produce cells with stem cell properties, by using specialized ... These ,iPS, stem cells are said to be "pluripotent,: they ...
... the International Osteoporosis Foundation (IOF) is releasing a 24-page ... strong muscles. Professor Heike Bischoff-Ferrari, director Centre ... City Hospital and author of the report, stated, "Put ... optimize your bone health by following three essential steps." ...
... In findings with major implications for the genetics of cancer ... (BIDMC) and two other science teams in New York City ... and showed how it may work to drive cancer and ... in the journal Cell describe aspects of what ...
... could help identify the manufacturers of designer ,legal high, drugs ... Strathclyde in Glasgow. The drugs, known by names such ... salts, plant food and incense, mimic the effects of illegal ... ,designer drugs, can be dangerous, many have not yet been ...
... , THURSDAY, Oct. 13 (HealthDay News) -- ... have more relationship problems, according to a new study. ... and possessions can take a toll on couples, happiness ... Brigham Young University analyzed relationship evaluations completed by more ...
Cached Medicine News:Health News:Young Children Collaborate Better Than Chimps 2Health News:Steps towards the use of adult stem cells for gene therapy 2Health News:Three steps to unbreakable bones on World Osteoporosis Day 2Health News:Researchers discover hidden genetic influence on cancer 2Health News:Researchers discover hidden genetic influence on cancer 3Health News:Researchers discover hidden genetic influence on cancer 4Health News:Researchers discover hidden genetic influence on cancer 5Health News:Tests to catch the makers of dangerous 'legal high' designer drugs 2Health News:Couples Can Pay a Price for Materialism 2
... Are Turned 90 Degrees To Allow ... While Incising Tissue. ,Special Mirror-Polished Double Footplate ... Blade Extension Settings Of 0.5mm, 0.55mm, ... Extension.,1mm Wide Snub Nose Diamond Blade ...
... Unique In-Line Footplates Are Turned ... Of The Diamond Blade While Incising ... Precise Blade Depth Penetration.,Pre-Set Blade Extension ... Full Retraction And Full Extension.,1mm Wide ...
... 23g Tube Allows Use Through A ... More Comfortable Approach To The Incision.,Cystotome ... Capsule To Initiate And Complete A ... Weight For Improved Ergonomic Feel. Ideal ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Medicine Products: